Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 526-534

  Wang, Xiaofang ^a   Harris, Peter C ^a   Somlo, Stefan ^b   Batlle, Daniel ^c   Torres, Vicente E ^a,d  

^a Mayo Clinic   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Calcimimetic; Cyclic AMP; PCK rat; Pkd2 WS25 mouse; Polycystic kidney disease

Indexed keywords

AQUAPORIN 2; CALCIUM; CALCIUM SENSING RECEPTOR; POTASSIUM; SODIUM; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HYPERPHOSPHATEMIA; HYPOCALCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; MALE; MORPHOMETRICS; NONHUMAN; NORTHERN BLOTTING; OSMOTIC DIURESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION; URINE VOLUME; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; AQUAPORIN 2; CALCIUM; CYCLIC AMP; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, MUTANT STRAINS; RECEPTORS, CALCIUM-SENSING; RECEPTORS, VASOPRESSIN; RNA, MESSENGER;

EID: 58449091830     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn527     Document Type: Article

References (39)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301
2. Gunay-Aygun M, Avner ED, Bacallao RL et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a First National Institutes of Health/Office of Rare Diseases conference. J Pediatr 2006; 149: 159-164
3. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2: 40-54
4. Pazour GJ, San Agustin JT, Follit JA et al. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 2002; 12: R378-R380
5. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are colocalized in renal cilia. J Am Soc Nephrol 2002; 13: 2508-2516
6. Nauli SM, Alenghat FJ, Luo Y et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33: 129-137
7. Ward CJ, Yuan D, Masyuk TV et al. Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol Genet 2003; 12: 2703-2710
8. Praetorius HA, Spring KR. Removal of the MDCK cell primary cilium abolishes flow sensing. J Membr Biol 2002; 232: 1042-1044
9. Wang S, Zhang J, Nauli SM et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 2007; 27: 3241-3252
10. Koulen P, Cai Y, Geng L et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 2002; 4: 191-197
11. 2+ signaling. J Biol Chem 2005; 280: 41298-41306
12. 2+ increase in the inhibition of intracellular cAMP content. Cell Signal 1999; 11: 651-663
13. Yamaguchi T, Nagao S, Kasahara M et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 1997; 30: 703-709
14. Gattone VH, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Med 2003; 9: 1323-1326
15. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med 2004; 10: 363-364
16. Wallace DP, Rome LA, Sullivan LP et al. cAMP-dependent fluid secretion in rat inner medullary collecting ducts. Am J Physiol Renal Physiol 2001; 280: F1019-F1029
17. Yamaguchi T, Nagao S, Wallace DP et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 2003; 63: 1983-1994
18. Hanaoka K, Guggino W. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11: 1179-1187
19. Yamaguchi T, Wallace DP, Magenheimer BS et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004; 279: 40419-40430
20. Yamaguchi T, Hempson SJ, Reif GA et al. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006; 17: 178-187
21. Wang X, Gattone II VH , Harris PC et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-851
22. Masyuk TV, Masyuk AI, Torres VE et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116
23. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006; 109: 339-365
24. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 2007; 3: 122-133
25. 2+ oscillations. J Cell Biol 2005; 171: 303-312
26. 2+/polyvalent cation-sensing protein in rat kidney. Am J Physiol 1998; 274: F611-F622
27. Ward DT, Riccardi D. Renal physiology of the extracellular calcium-sensing receptor. Pflugers Arch 2002; 445: 169-176
28. Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271: C103-C111
29. 2+ on apical K+ channels in rat TAL. Am J Physiol 1997; 273: F421-F429
30. Wang W, Li C, Kwon TH et al. AQP3, p-AQP2, and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by cAMP-PDE inhibitors. Am J Physiol Renal Physiol 2002; 283: F1313-F1325
31. Fox J, Lowe SH, Petty BA et al. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290: 473-479
32. Sands JM, Naruse M, Baum M et al. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 1997; 99: 1399-1405
33. Sands JM, Flores FX, Kato A et al. Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. Am J Physiol 1998; 274: F978-F985
34. Lager DJ, Qian Q, Bengal RJ et al. The PCK rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001; 59: 126-136
35. Bustamante M, Hasler U, Leroy V et al. Calcium-sensing receptor attenuates AVP-induced aquaporin-2 expression via a calmodulin-dependent mechanism. J Am Soc Nephrol 2008; 19: 109-116
36. Yamaki M, McIntyre S, Rassier ME et al. Cyclic 3′,5′-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am J Physiol 1992; 262: F957-F964
37. i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ Res 2005; 96: 873-880
38. Klein JD, Frohlich O, Blount MA et al. Vasopressin increases plasma membrane accumulation of urea transporter UT-A1 in rat inner medullary collecting ducts. J Am Soc Nephrol 2006; 17: 2680-2686
39. Canaff L, Petit JL, Kisiel M et al. Extracellular calcium-sensing receptor is expressed in rat hepatocytes. Coupling to intracellular calcium mobilization and stimulation of bile flow. J Biol Chem 2001; 276: 4070-4079